|
Factors associated with virological response (univariate and multivariate analyses). |
||||
| Univariate analysis |
Multivariate analysis |
|||
|
|
||||
| OR (95% CI) |
p |
OR (95% CI) |
||
|
|
||||
| Rescue with PI/rit |
3.93 (0.88 to 17.56) |
0.07 |
7.57 (0.58 to 99.31) |
0.12 |
| Previous length of ARV exposure |
0.99 (0.97 to 1.01) |
0.29 |
- |
- |
| Previous length of PI exposure |
0.98 (0.94 to 1.01) |
0.19 |
- |
- |
| No. previous PIs exposure |
0.61 (0.29 to 1.25) |
0.18 |
0.23 (0.06 to 0.89) |
0.03 |
| No. susceptible drugs according to CCO1 |
2.16 (1.02 to 4.57) |
0.04 |
0.22 (0.03 to 1.57) |
0.13 |
| No. susceptible drugs according to CCO2 |
4.99 (1.55 to 16.05) |
0.01 |
5.34 (1.23 to 23.11) |
0.02 |
| No. active PIs in the salvage regimen according to virtual phenotype |
6.60 (1.40 to 31.05) |
0.02 |
0.64 (0.03 to 11.58) |
0.76 |
| No. NAMs |
0.85 (0.54 to 1.32) |
0.46 |
- |
- |
| No. protease resistance mutations |
0.81 (0.62 to 1.06) |
0.12 |
0.89 (0.56 to 1.46) |
0.65 |
|
(OR: Odds ratio; PI: protease inhibitor; RIT: ritonavir; ARV: antiretroviral treatment; CC01: lower clinical cut-off; CC02: upper clinical cut-off; NAMs: nucleotide analogue mutations: M41L, D67N, K70R, L210W, T215Y/F y K219Q/E/R/S/N) | ||||
Larru et al. BMC Infectious Diseases 2007 7:55 doi:10.1186/1471-2334-7-55 |
||||